# How To Avoid The Marijuana Munchies This Summer > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/how-to-avoid-the-marijuana-munchies-this-summer/ > **Published:** 2026-08-01T07:44:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:17:36-04:00 > **Clinical Summary:** Evidence on THCV appetite suppression and cannabis strains. What clinicians need to know about cannabinoid appetite effects. --- ✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. THCResearchSafetyPolicyPainAnxietyMental Health Why This Matters Clinicians should understand that cannabinoid composition, particularly THCV content, may influence appetite effects in cannabis users, which is relevant for patients managing appetite-related conditions or weight. This distinction between strain types could help inform discussions about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) with patients who have concerns about increased appetite or those using cannabis for therapeutic purposes where appetite changes matter clinically. Clinical Summary Current evidence suggests that tetrahydrocannabivarin (THCV), a minor cannabinoid found in certain cannabis strains, may produce appetite suppression rather than the [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) commonly associated with THC-dominant products. This distinction has potential clinical relevance for patients using cannabis therapeutically, particularly those managing conditions where [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) is undesirable or contraindicated, such as certain metabolic disorders or [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) concerns. However, human clinical data directly comparing THCV-rich strains to traditional high-THC varieties remain limited, and individual responses to different cannabinoid profiles vary considerably based on genetics, tolerance, and consumption patterns. For clinicians counseling patients on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), awareness of cannabinoid diversity beyond THC concentration alone may improve shared decision-making and help identify strains better suited to individual patient needs and side effect profiles. Patients interested in [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) who wish to avoid [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) should discuss THCV-dominant strain options with their dispensary or healthcare provider, though they should be aware that strain labeling accuracy and cannabinoid content verification remain inconsistent across most markets. Dr. Caplan’s Take “The early signals around THCV and appetite suppression are worth watching, and I do hear this anecdotally from patients, but we’re still working with limited human data here—most of what we know comes from in vitro work and consumer reports rather than controlled trials. Until we see properly designed studies in humans, I tell patients that individual variation is significant and strain composition alone isn’t a reliable predictor of how their appetite will respond.” Clinical Perspective 🍽️ The emerging interest in THCV-dominant cannabis strains as appetite-suppressant alternatives reflects a rational consumer response to a well-documented cannabinoid effect, though clinicians should approach this trend with appropriate skepticism given the limited peer-reviewed evidence base. While some in vitro and animal studies suggest THCV may have appetite-reducing properties distinct from THC, human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are sparse, and the quality, composition, and labeling accuracy of commercially available “THCV strains” remain largely unverified. Patients interested in cannabis for conditions where appetite suppression or [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) is relevant should be counseled that strain selection alone is an unreliable strategy, given variable cannabinoid ratios between and within products and significant individual metabolic variation. Rather than endorsing specific strain recommendations, providers can acknowledge patient interest while emphasizing the importance of third-party lab testing, documenting actual cannabinoid content, and 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20How%20To%20Avoid%20The%20Marijuana%20Munchies%20This%20Summer%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71925)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71925)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20How%20To%20Avoid%20The%20Marijuana%20Munchies%20This%20Summer%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71925)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://thefreshtoast.com/cannabis/how-to-avoid-the-marijuana-munchies-this-summer/](https://thefreshtoast.com/cannabis/how-to-avoid-the-marijuana-munchies-this-summer/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).